Valion Bio, Inc.
VBIO
$1.10
-$0.01-0.90%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | 69.77% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | 69.77% | |||
| Cost of Revenue | -- | 809.38% | |||
| Gross Profit | -- | -368.52% | |||
| SG&A Expenses | -50.47% | 11.03% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -36.36% | 30.15% | |||
| Operating Income | 20.46% | -28.39% | |||
| Income Before Tax | 24.35% | -34.44% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 24.35% | -34.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.75% | -34.44% | |||
| EBIT | 20.46% | -28.39% | |||
| EBITDA | 20.58% | -28.45% | |||
| EPS Basic | 42.89% | 8.75% | |||
| Normalized Basic EPS | 70.53% | 14.33% | |||
| EPS Diluted | 42.89% | 8.75% | |||
| Normalized Diluted EPS | 70.53% | 14.33% | |||
| Average Basic Shares Outstanding | -12.52% | 49.87% | |||
| Average Diluted Shares Outstanding | -12.52% | 49.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||